In 2015, the combination of lumacaftor (LUM) and ivacaftor (IVA) (CFTR corrector and potentiator, respectively) became the first protein therapy approved for F508del homozygous patients (about 40% of patients with CF) (7, 8). The gene discussed is CFTR; the disease is cystic fibrosis.